SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

---

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):  May 17, 2012

 

Derma Sciences, Inc.

(Exact name of registrant as specified in its charter)

 

Pennsylvania	1-31070	23-2328753
(State or other jurisdiction	(Commission	(IRS employer
of incorporation)	File Number)	identification number)

 

214 Carnegie Center, Suite 300

Princeton, NJ  08540

(609) 514-4744

(Address including zip code and telephone

number, of principal executive offices)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 8.01  Other Events

 

In the proxy materials of Derma Sciences, Inc. (the “Company”), made available or, upon request, mailed to shareholders on or about April 17, 2012, for its upcoming annual meeting, Edward J. Quilty was identified as a member of the Nominating and Corporate Governance Committee (the “Nominating Committee”) of the Board of Directors of the Company.  His appointment this past year to the Nominating Committee was an oversight, in that executive officers are precluded from serving on such Committee. In conjunction with discussions with representatives of the Nasdaq Stock Market, Mr. Quilty, on May 17, 2012, resigned from the Nominating Committee, effective immediately.

 

 

  Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	DERMA SCIENCES, INC.
	By:	/s/ John E. Yetter
		John E. Yetter, CPA
		Vice President and Chief Financial Officer

Date:  May 18, 2012